MedTrace Logo

Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer

NCT07403916 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2026-02-11

No results posted yet for this study

Summary

Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease.

NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy.

The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse.

The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management.

This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.

Conditions

  • Gastric Cancer (GC)
  • Next-generation Sequencing
  • Molecular Analysis

Interventions

DIAGNOSTIC_TEST

Next-generation sequencing

Technology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena

Sponsors & Collaborators

  • P. Herzen Moscow Oncology Research Institute

    lead OTHER_GOV

Principal Investigators

  • Andrey Ryabov, MD, PhD · P.Herzen Moscow Oncological Research Institute

  • Vakhtang Begiashvili, PhD student · P.Herzen Moscow Oncological Research Institute

  • Vladimir Khomyakov, MD, PhD · P.Herzen Moscow Oncological Research Institute

  • Nadezhda Volchenko, MD, PhD · P.Herzen Moscow Oncological Research Institute

  • Shatalov Peter, PhD · P.Herzen Moscow Oncological Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-10
Primary Completion
2025-12-31
Completion
2026-06-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07403916 on ClinicalTrials.gov